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IntroductIon 
Krüppel-like factors (KLFs) comprise a highly 
conserved transcription factor family of 17 members 
[1]. They are known to regulate cellular functions such 
as proliferation, apoptosis, migration, differentiation, and 
pluripotency [2–4]. KLF4 is the best-studied member of 
the family and it is one of the factors in the “Yamanaka 
cocktail”, which upon transfection, allows the conversion 
of adult cells into induced pluripotent stem cells [5]. 
KLF4 has been extensively studied in the context 
of tumors and current data suggest that it can either act 
as tissue-specific tumor-inhibiting or -promoting gene 
with the underlying mechanism remaining unclear [6, 7]. 
KLF4 has been reported to have tumor-suppressive 
functions in various tumors, including tumors of the 
colon, bladder, prostate, and stomach [8–13], while it acts 
as a pro-tumorigenic gene in oral and skin squamous cell 
carcinomas [14, 15]. 
The role of KLF4 in breast cancer remains less clear 
and contradictory data exist. It is believed that KLF4 is 
expressed at low levels in normal breast epithelium, but 
over-expressed during breast tumor progression [16]. 
Furthermore, increased nuclear KLF4 expression is 
considered to be a marker of an aggressive phenotype in 
early-stage infiltrating ductal carcinoma [17]. Additionally, 
KLF4 plays a prominent role in the maintenance of the 
cancer stem cell-like population, which promotes cell 
migration and invasion [18]. However, the role of KLF4 as 
a putative tumor-promoting gene in breast cancer remains 
unresolved: extensive analyses of the Oncomine database 
revealed lower KLF4 mRNA levels in breast tumor 
tissues, compared with normal tissues, in 9 of 11 data sets 
and indicated that the levels are inversely correlated with 
tumor grade [19]. Moreover, two new genetic variants in 
the estrogen-receptor positive breast cancer susceptibility 
locus 9q31.2 [20] have been recently identified that target 
KLF4 via long-range chromatin interactions [21]. These 
data show that lower levels of KLF4 are associated with 
increased breast cancer risk and promote KLF4 as a tumor 
suppressor-like gene [20, 21]. Similarly, KLF4 inhibits 
epithelial-mesenchymal-transition (EMT) and metastasis 
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ABStrAct
Krüppel-like factor 4 (KLF4), a transcription factor involved in both tumor 
suppression and oncogenesis in various human tumors, is subject to alternative 
splicing that produces KLF4α. KLF4α is primarily expressed in the cytoplasm because 
it lacks exon 3 of KLF4, which contains the nuclear localization signal. The role of 
KLF4 in breast cancer remains unclear and nothing is known yet about the expression 
and function of the isoform KLF4α. Here, we show that KLF4α is expressed in normal 
and tumoral tissue of the breast and provide evidence that the KLF4α/KLF4(full-
length) (FL) ratio is increased in tumors compared to corresponding normal tissue. 
Forced increase of the KLF4α/KLF4(FL) ratio in the metastatic breast cancer cell line 
MDA-MB-231 decreases the levels of E-Cadherin, p21Cip1, and p27Kip1, three known 
KLF4(FL) target genes, and stimulates cell proliferation. We suggest that cytoplasmic 
KLF4α binds to KLF4(FL) and retains it in the cytoplasm thereby antagonizing the 
gene regulatory activities of KLF4(FL) in the nucleus. Our results establish KLF4α as 
a KLF4 isoform that opposes the function of KLF4(FL) and as an important factor in 
the complex and unresolved role of KLF4(FL) in breast carcinogenesis.
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in breast cancer models [22–24]. Thus, KLF4’s role in 
breast tumors remains a conundrum.
Only recently, KLF4 isoforms have been identified 
[25–27]. One of the main KLF4 isoforms, KLF4α, has 
been shown to be over-expressed in pancreatic cancers and 
to correlate with the aggressiveness of tumors and poor 
patient prognosis [26]. 
Here, we aimed to elucidate whether KLF4α 
is expressed in breast cancer cells and, if so, whether 
increased KLF4α levels might explain some of the 
complexity of KLF4’s role in breast tumorigenesis. 
We have established that KLF4α is expressed in the 
cytoplasm of breast cancer cells and present evidence 
that an increased KLF4α/KLF4(FL) ratio is often found 
in tumors compared to normal tissue. Our data suggest 
that KLF4α acts as a dominant KLF4(FL) antagonist 
and prevents nuclear translocation of KLF4(FL), thereby 
altering the transcriptional landscape in breast cancer cells. 
We provide evidence that KLF4α has tumor-promoting 
functions and that its expression may play a significant 
role in KLF4’s complex functions in breast cancer. 
reSultS
detection of KLF4α in human breast cancer cells
Unresolved data on the role of KLF4 during breast 
carcinogenesis [4], as well as the identification of KLF4α, 
a KLF4 isoform, as a tumor-promoting gene in pancreatic 
cancer [26], prompted us to study KLF4α expression 
in breast cancer cells. To test whether normal and/or 
breast cancer cells express KLF4α, we used MCF10A 
and MDA-MB-231 cells and performed RT-PCR with 
primers flanking the KLF4 gene (Figure 1A, 1B). A 
product of ~1440 bp was amplified in both cell lines, 
while a ~440 bp amplicon was detectable in the metastatic 
MDA-MB-231 cells only (Figure 1A). Sequencing of 
these PCR products revealed KLF4(FL) (1440 bp band; 
UniProtKB-O43474; KLF4 isoform 2) and KLF4α 
(440 bp; UniProtKB-O43474-5). KLF4α is a KLF4 
isoform that lacks exon3, leading to a frameshift in exon4 
and to a premature Stop codon in exon5 (Figure 1B and 
Supplementary Figure S1). All three zinc finger domains 
of KLF4(FL) and its nuclear localization signal (NLS) are 
not present in KLF4α. 
Next, we wanted to quantitatively study RNA levels 
of the two KLF4 variants in a panel of breast cancer cell 
lines (MCF7, T47D, MDA-MB-175, and MDA-MB-231), 
the normal human breast cell line (MCF10A), and also in 
samples from patients with ductal carcinoma. Specificity 
of qPCR primers recognizing KLF4(FL) and KLF4α, 
respectively, as well as primers that detect both KLF4 
variants (“KLF4 all”) (Supplementary Figure S2) allowed 
us to study breast cancer-associated KLF4 splicing in more 
detail. KLF4 all levels were variable in all our samples 
analyzed (Figure 1C, left). KLF4(FL) levels mostly 
paralleled those of KLF4 all, with the exception of the 
carcinoma patient 1 (Figure 1C, right). In three out of 
the four breast cancer cell lines tested, KLF4α RNA was 
readily detectable (Figure 1C bottom). Only T47D cells 
were negative for KLF4α. KLF4α was not detectable in 
the normal breast cell line MCF10A, which confirmed our 
RT-PCR (Figure 1A). The relative expression patterns of 
KLF4(FL) and KLF4α in the cell lines were very similar. 
In the two patient samples, however, KLF4α showed 
higher expression than in cell lines, which was in contrast 
to KLF4(FL). Since both KLF4 variants were detectable in 
most of the breast cancer samples, we wished to determine 
the KLF4α/KLF4(FL) ratio in each sample. KLF4α/
KLF4(FL) ratios were variable across the samples, but 
highest in the carcinoma patients, which was due to their 
elevated KLF4α (Figure 1D).
So far, there is only limited data on KLF4α 
expression in cancer cell lines [25, 26]. Thus, we decided 
to screen an additional panel of 21 human cancer cell 
lines from various origins for the expression of KLF4 
all, KLF4(FL), and KLF4α (Supplementary Figure S3). 
This analysis demonstrated that KLF4α transcripts are 
expressed in 84% of the cancer cell lines tested, (including 
breast cancer; Supplementary Table 1).
KLFα in human tumors
To extend this study and to analyze clinically 
relevant specimens, we used a TissueScanTM Cancer and 
Normal Tissue cDNA Array. This array consists of five 
breast, kidney, lung, and ovary cancer samples and one 
normal control for each tissue (Supplementary Figure S4). 
qPCR analysis showed that KLF4α transcripts were 
detectable in all control tissues (Figure 2A, right). KLF4α 
expression was two-fold higher in normal kidney, lung, 
and ovarian tissue compared to normal breast (data not 
shown). KLF4α RNA was also prominently expressed 
in all the different tumor patients. Comparing the levels 
of KLF4α in control and tumor samples, no consistent 
difference could be observed in kidney, lung, and ovarian 
tumor patients. Only in the five breast cancer patients 
KLF4α was consistently and prominently over-expressed 
compared to control tissue (Figure 2A right). KLF4(FL) 
was detectable in all normal tissues as well (Figure 2A, 
left) with highest expression in ovarian tissue and lowest 
levels in breast tissue (data not shown). In ovarian tumors 
all patients displayed a prominent reduction of KLF4(FL) 
levels confirming literature on tumor-suppressive 
functions of KLF4 in ovarian cancer [28]. When we 
determined the ratio KLF4α/KLF4(FL) in all these clinical 
samples, we noticed an appreciable increase of the ratio 
in 4/5 breast, 3/5 kidney, 3/5 lung, and 5/5 ovary cancer 
samples compared to their corresponding healthy tissues 
(Figure 2A bottom panels).
To further solidify our hypothesis of an increased 
KLF4α/KLF4(FL) ratio in tumors, we used a matched 
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pair RNA sample from an invasive ductal carcinoma and 
adjacent normal tissue (Figure 2B). KLF4 all, KLF4(FL) 
as well as KLF4α RNA levels were all prominently 
reduced in the tumor sample compared to control. Still, 
a significant increase of the KLF4α/KLF4(FL) ratio in the 
tumor could be determined (Figure 2B).
Cytoplasmic localization of KLF4α 
To study KLF4(FL) and KLF4α function in breast 
cancer cells, we cloned both cDNAs into mammalian 
expression plasmids and transfected MDA-MB-231 cells. 
The KLF4 antibody used in this study was raised against 
a C-terminal peptide corresponding to human KLF4 aa 
300–400 and therefore, only detected KLF4(FL) 
(~65 kDa). KLF4α (~18 kDa) could be detected by its 
myc-tag as well as by the antibody anti-GN330 [26] 
(Figure 3A). KLF4(FL) contains a NLS in exon 3 (Figure 
1B), which is responsible for its nuclear localization 
(Figure 3B). In contrast, KLF4α, lacking exon3, was 
localized primarily in the cytoplasm of MDA-MB-231 cells 
(Figure 3B, right panel). Complementary localization of 
KLF4(FL) and KLF4α was further confirmed by preparing 
cytoplasmic and nuclear protein extracts of transfected 
MDA-MB-231 cells (Figure 3C). KLF4α expression was 
only detected in the cytoplasmic fraction, while the vast 
majority of KLF4(FL) was present in the nuclear fraction 
(Figure 3C),which confirmed our staining results.
Specificity of the anti-GN330 antibody for KLF4α 
(Figure 3A) allowed us to analyze endogenous KLF4α 
protein levels in our breast cancer cells. KLF4α was 
detected in extracts of MDA-MB-175, MDA-MB-231, 
and 172 (mutated p53 showing high KLF4α RNA levels 
(Supplementary Figure S3C)), but not in T47D and 
MCF10A cells (Figure 3D). These results confirmed our 
RNA analyses (Figure 1C), suggesting a good correlation 
between KLF4α RNA and protein levels.
Effects of KLF4(FL) and KLF4α in MDA-
MB-231 cells
Reported tumor-suppressive effects of forced 
KLF4 expression include the induction of the epithelial 
cell-adhesion molecule E-Cadherin and the cell cycle 
inhibitors p21Cip1 and p27Kip1 via direct binding of KLF4 
to the respective promoter elements [22, 29, 30]. In our 
panel of breast cancer cells we detected strong variation 
of endogenous E-Cadherin, p21Cip1, and p27Kip1 RNA and 
protein levels. High E-Cadherin, p21Cip1, and p27Kip1 levels 
mostly correlated with high expression of KLF4(FL) in the 
breast cancer cell lines (Figures 1C, 4A). MDA-MB-231 
cells, which are believed to have undergone an EMT, 
hardly express any E-Cadherin and p21Cip1 (Figure 4A, 4B).
Forced expression of KLF4(FL) in the highly 
metastatic MDA-MB-231 cells robustly restored 
E-Cadherin RNA as well as protein expression (Figure 4C 
left panel, D lane 3). Similarly, KLF4(FL) over-expression 
induced p21Cip1, while it was not able to stimulate p27Kip1 
expression in MDA-MB-231 cells (Figure 4C right 
panel, 4D). These results suggest that KLF4(FL) appears 
to enforce an epithelial phenotype and to induce growth 
arrest by increasing E-Cadherin and p21Cip1 levels, 
respectively. Indeed, KLF4(FL) over-expressing MDA-
MB-231 cells display a more cobblestone-like, epithelial 
morphology and have growth disadvantages compared to 
control cells (data not shown). In contrast, an increased 
KLF4α/KLF4(FL) ratio by forced KLF4α expression 
in MDA-MB-231cells was not able to either induce 
E-Cadherin or p21Cip1, but it decreased p27Kip1 levels 
compared to control (Figure 4C, 4D). Comparable results 
were obtained in KLF4(FL) and KLF4α over-expressing 
MCF7 cells (data not shown)
KLF4α antagonizes KLF4(FL) function 
Next, we wanted to know whether an increased 
KLF4α/KLF4(FL) ratio, which we had identified in 
tumors, might have consequences for KLF4(FL) target 
genes. Therefore, we generated KLF4α/KLF4(FL) 
imbalances and analyzed their effects on KLF4’s ability 
to induce E-Cadherin and p21Cip1 in MDA-MB-231 cells. 
Co-transfection of different amounts of KLF4(FL) and 
KLF4α, respectively, altered their individual protein 
levels in a dose-dependent manner, thereby changing the 
KLF4α/KLF4(FL) ratios (Supplementary Figure S5 and 
Figure 5C). Increased KLF4α/KLF4(FL) ratios abrogated 
KLF4(FL)-mediated induction of E-Cadherin and p21Cip1 
(Figure 5A, 5B left panels, 5C). In contrast, similar 
ratios of KLF4(FL)/pCMV6 ratios were still capable of 
inducing both genes (Figure 5A, 5B right panels). Our data 
demonstrate that increased KLF4α/KLF4(FL) ratios, either 
generated by reduction of KLF4(FL) or gain of KLF4α, 
antagonizes KLF4(FL)-mediated induction of E-Cadherin 
and p21Cip1. 
KLF4α interacts with KLF4(FL)
An antagonistic function of KLF4α on KLF4(FL) 
suggests that there might be an interaction of the two 
proteins. We hypothesized that KLF4α binds KLF4(FL) 
in the cytoplasm, thereby preventing its translocation 
into the nucleus. To study this possibility, we co-
transfected MDA-MB-231 cells with a 1:1 ratio of either 
KLF4α-myc/KLF4(FL) or KLF4(FL)-myc/pCMV6 
and analyzed the cellular localization of KLF4(FL) by 
immunofluorescence (Figure 6A, 6B). KLF4(FL) was 
primarily localized in the nucleus in KLF4(FL)/pCMV6 
transfected cells (Figure 6A). In contrast, presence of 
KLF4α significantly disturbed the nuclear localization 
of KLF4(FL), as evidenced by cytoplasmic staining 
patterns (Figure 6B). Typical examples are shown in 
Figure 6B. In the bottom row of Figure 6B, one out of 
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three cells shows an exclusive nuclear staining (indicated 
by the dotted line) for KLF4(FL). This cell does not 
express KLF4α, whereas the two other cells that express 
KLF4α, have KLF4(FL) in the cytoplasm as well. These 
observations were confirmed by quantifying the three cells 
of Figure 6B bottom row by linescan plots (Figure 6C). 
We further quantified these findings in more than 100 
transfected, KLF4α-positive MDA-MB-231 cells. We 
determined a statistically significant difference in the 
percentage of cells with exclusively nuclear KLF4(FL) in 
KLF4(FL)/pCMV6 versus KLF4(FL)/KLF4α transfected 
cells (Figure 6D). These data let us speculate that KLF4α 
sequesters KLF4(FL) in the cytoplasm and consequently, 
KLF4(FL) levels in the nucleus should be decreased in 
the presence of KLF4α. To test this hypothesis, we co-
transfected MDA-MB-231 cells with different KLF4α/
KLF4(FL) ratios and analyzed their nuclear fractions for 
the levels of KLF4(FL). A prominent decrease of nuclear 
KLF4(FL) was observed in the presence of KLF4α 
compared to control (pCMV6) (Figure 6E). Finally, we 
assessed the possibility of a direct or indirect interaction 
between KLF4α and KLF4(FL) in the cytoplasm of MDA-
Figure 1: Detection of KLF4α in human breast cancer cells. (A) RT-PCR analysis of KLF4 in MDA-MB-231 and MCF10A 
cells. Both cell lines show the KLF4(FL) band (~1440 bp), whereas the KLF4α band (~440 bp) is only detectable in MDA-MB-231 cells. 
(B) Schematic representation of the KLF4 protein structure (top) and the KLF4 gene and its variants in MDA-MB-231 cells (bottom). The 
KLF4 gene is located on chromosome 9 (reverse strand), contains 5 exons, which gives rise to a KLF4(FL) protein of 479aa. Skipping 
of exon3 produces KLF4α (118aa). Numbers indicate the amino acids. AD: activation domain; ID: inhibitory domain, ZF: zinc fingers; 
NLS: nuclear localization signal; aa: amino acids; white boxes: untranslated exons; light grey boxes: shared sequence between KLF4(FL) 
and KLFα; dark grey boxes: novel sequence in KLF4α; arrows: primers used in A). (c) qPCR analysis of a normal human breast cell 
line (MCF10A) compared to four human breast cancer cell lines and two human ductal breast carcinoma patients for the genes KLF4 all, 
KLF4(FL), and KLF4α. Note that KLF4α is detectable in three out of the four breast cancer cell lines and that the two breast cancer patient 
samples show high levels of KLF4α compared to cells. Data are expressed as the mean +/– SEM. n = 3. TBP: TATA-Box binding protein. 
*CT values ≥ 34. (d) RNA ratio of KLF4α/KLF4(FL) indicates highest ratio in the two cancer patient samples.
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MB-231 cells by co-IP experiments. Indeed, KLF4α and 
KLF4(FL) associate with each other as evidenced by 
the appearance of a KLF4(FL) band in the KLF4α-myc-
immunoprecipitated sample (Figure 6F). 
KLF4α stimulates breast cancer cell 
proliferation 
Finally, we wanted to learn more about the 
functional consequences of increased KLF4α/KLF4(FL) 
ratios in MDA-MB-231 cells. First, we analyzed the 
actin cytoskeleton of KLF4α-over-expressing MDA-
MB-231cells compared to control. While the control 
cells showed high actin expression throughout the cells, 
we noticed prominent cortical actin and mostly absence 
of intracellular actin in the KLF4α-cells, which also 
seemed to be larger than controls (Figure 7A). Since 
distinct actin network patterns might reflect changes in 
cellular motility, we wanted to check whether KLF4α 
stimulates cancer cell migration. Boyden chamber assays 
as well as scratch wounds were performed and analyzed, 
but no significant difference in the migratory behavior of 
KLF4α over-expressing MDA-MB-231 cells compared 
to control was observed (data not shown). Finally, we 
tested the role of altered KLF4α/KLF4(FL) ratios on 
cell growth. While forced KLF4α expression in the 
normal mammary cell line MCF10A did not change 
proliferation, the growth rate of T47D and MDA-
MB-231 was increased upon KLF4α over-expression 
(Figure 7B). Hence, KLF4α only had a growth-
promoting effect on breast cancer cell lines, which was 
independent of their respective endogenous total KLF4 
Figure 2: KLF4α/KLF4(FL) imbalance in tumors. (A) qPCR analysis for KLF4(FL) and KLF4α in TissueScans containing 5 
different tumor samples (T1-5) and a normal control tissue (N). Consistent increases of KLF4α/KLF4(FL) are detected in 4/5 breast, 3/5 
kidney, 3/5 lung, and 5/5 ovary cancer samples compared to controls. (B) A matched pair of a ductal carcinoma breast patient was analyzed 
by qPCR for KLF4(FL) and KLF4α. While KLF4all, KLF4(FL) and KLF4α RNA levels are decreased in tumors, there is a prominent 
KLF4α/KLF4(FL) ratio imbalance in the tumor sample compared to the control tissue. TBP: TATA-Box binding protein. Data are expressed 
as the mean +/– SEM. n = 3. *p ≤ 0.05 (tumor versus normal).
Oncotarget45613www.impactjournals.com/oncotarget
levels (low in T47D, high in MDA-MB-231) (Figure 
1C). BrdU incorporation assays further demonstrated 
that increased KLF4α/KLF4(FL) ratios by forced KLF4α 
expression increased the fraction of cells within S phase 
(Figure 7B, bottom right). Thus, we propose KLF4α as a 
novel, so far neglected oncogenic factor, which clarifies 
the role of KLF4 in breast cancer. 
dIScuSSIon
It is well established that KLF4 has ambiguous roles 
in human breast cancer. The general discovery of KLF4 
variants [25–27] and our data on KLF4α as an antagonist 
of KLF4(FL) in breast cancer might shed new light on the 
role of KLF4 during breast tumorigenesis. 
Figure 3: Characterization of KLF4α expression. (A) MDA-MB-231 cells were transfected with the indicated plasmids and 
immunoblotted with α-KLF4, which only detects KLF4(FL), with α-myc, which detects both myc-tagged variants of KLF4, and with 
α-GN330, which specifically recognizes KLF4α. *background band. (B) Immunofluorescent stainings of transfected MDA-MB-231 cells 
24 h post-transfection show nuclear staining for KLF4(FL) and cytoplasmic staining for KLF4α. Hoechst stain was used for the visualization 
of nuclei. Scale bar: 50 µm (top); 10 µm (close-up). The bottom row indicates the secondary antibody only controls merged with the 
respective Hoechst staining (left side: goat-anti-rabbit IgG-FITC; right side: goat-anti-mouse IgG-FITC). (c) Transfected MDA-MB-231 
cells were extracted for the cytoplasmic and the nuclear fractions 36 hours after transfection and immunoblotted. KLF4α is only found in 
the cytoplasmic, GAPDH-positive fraction, whereas most of KLF4(FL) is present in the nuclear, LaminA/C-positive fraction. * background 
band. (d) Western blot analysis of protein extracts of the normal breast cell line (MCF10A), four breast cancer cell lines as well as a p53-
mutant Li Fraumeni cell line (172) in comparison to KLF4α-transfected MDA-MB-231 cells for KLF4α levels. Note that endogenous 
KLF4α (~18kDa) is detectable in MDA-MB-175, MDA-MB-231, and 172 cells. GAPDH: glyceraldehyde-3-phosphate dehydrogenase.
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In the current study, we analyzed the expression 
and function of the main KLF4 isoform, KLF4α, in breast 
cancer cells. We demonstrate that KLF4α is expressed 
in breast cancer cells and show that KLF4α is primarily 
localized in the cytoplasm. Strong evidence is presented 
that KLF4α sequesters KLF4(FL) in the cytoplasm through 
an association of KLF4α with KLF4(FL). Consequently, 
direct or indirect binding of cytoplasmic KLF4α to 
KLF4(FL) prevents KLF4(FL) from nuclear translocation 
and results in altered transcriptional regulation of 
KLF4(FL) target genes, such as E-Cadherin, p21Cip1, and 
p27Kip1. Chromatin IP’s have shown physical interaction 
of KLF4(FL) with the promoter of all three genes and 
KLF4-binding sites have been identified suggesting that 
Figure 4: Effects of forced expression of KLF4(FL) and KLF4α in MDA-MB-231 cells. (A) qPCR analysis of a normal 
human breast cell line (MCF10A) compared to 4 human breast cancer cell lines and two human ductal breast carcinoma patients for 
endogenous levels of E-Cadherin, p21Cip1 and, p27Kip1 shows various expression levels in the different samples. Note that E-Cadherin and 
p21Cip1 levels are very low in MDA-MB-231. Data are expressed as the mean +/– SEM. n = 3. (B) Western Blot analysis of the normal 
and cancerous breast cells for E-Cadherin, p21Cip1, p27Kip1 indicates that protein levels correlate with RNA levels. Normalized protein 
levels of three independent western blots have been quantified and plotted. (c) Forced expression of KLF4(FL) in MDA-MB-231 cells 
induces E-Cadherin as well as p21Cip1 RNA, but not p27Kip1. In contrast, forced expression of KLF4α does neither affect basal levels 
of E-Cadherin nor p21Cip1, but decreases p27Kip1. Data are expressed as the mean +/– SEM. n = 3. TBP: TATA-Box binding protein. 
*p ≤ 0.05 (KLF4(FL) versus pCMV6/KLF4α). (d) Response of E-Cadherin, p21Cip1, and p27Kip1 protein levels upon forced expression of 
KLF4(FL) and KLF4α, respectively, in MDA-MB-231 cells in comparison to the endogenous protein levels in MCF7. Normalized protein 
levels of three independent western blots have been quantified and plotted. *p ≤ 0.05 E-Cadherin in KLF4(FL) versus KLF4α cells; **p 
≤ 0.05 p21Cip1 in KLF4(FL) versus KLF4α cells; ***p ≤ 0.05 p27Kip1 in KLF4α versus KLF4(FL) cells. Note that KLF4α antagonizes 
KLF4(FL)-mediated target gene regulation and decrease p27Kip1. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. *background band. 
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KLF4(FL) transactivates E-Cadherin, p21Cip1, and p27Kip1 
[22, 29, 30]. We confirmed the ability of KLF4 to induce 
levels of E-Cadherin and p21Cip1 in the highly metastatic 
breast cancer cell line MDA-MB-231, but did not observe 
an increase of p27Kip1 upon forced KLF4 expression. 
However, increasing the KLF4α/KLF4(FL) ratio in MDA-
MB-231 strongly antagonized the effect of KLF4(FL) 
and decreased levels of E-Cadherin, p21Cip1, as well as 
p27Kip1. Augmented KLF4α/KLF4(FL) ratios increased 
the fraction of cells within S phase and promoted a pro-
tumorigenic phenotype by opposing the tumor-suppressive 
functions of KLF4(FL). Since we detected KLF4α in 
human cancers of various origin, we speculate that our 
findings in breast cancer may be relevant for other tumors 
as well.
An antagonistic effect of KLF4α on KLF4(FL) 
function can be explained by two potential mechanisms: 
Either there is an interaction of KLF4α with KLF4(FL) 
in the cytoplasm, which then retains KLF4(FL) in the 
cytoplasm and inhibits nuclear translocation of KLF4(FL), 
or KLF4α sequesters important co-factors in the cytoplasm 
required for KLF4(FL)-mediated gene regulation in the 
nucleus. We cannot exclude the latter, but we showed that 
KLF4α is associated with KLF4(FL) in the cytoplasm and 
that nuclear KLF4(FL) levels are decreased in the presence 
of KLF4α compared to control cells. There is no evidence 
in the literature that KLF4 can form dimers. Therefore, 
the detailed molecular mechanism how KLF4α associates 
with KLF4(FL) remains to be elucidated. It is plausible 
to speculate that alternative splicing produces novel 
motifs in KLF4α that are responsible for the interaction or 
association with KLF4(FL). However, we did not identify 
any obvious structural motifs in KLF4α. 
Similar to our study on KLF4, it has been shown 
that splicing deregulation of KLF6 results in a specific 
variant, KLF6-v1, that is associated with an increased risk 
of various cancers and opposes KLF6(FL) effects [31–37]. 
It is believed that intronic and/or exonic site mutations 
and splicing factor alterations are the main reasons for 
aberrant splicing to occur in tumors [38]. We do not 
have any data on mutations affecting KLF4 splicing or 
splicing factor level alterations in human tumors. In the 
case of KLF6, it has been shown that a single germline 
DNA polymorphism is responsible for the generation of 
Figure 5: KLF4α antagonizes KLF4(FL)-mediated effects on E-Cadherin and p21. (A) MDA-MB-231 cells were transiently 
transfected with different ratios of KLF4α and KLF4(FL) followed by qPCR analysis for E-Cadherin. Increasing amounts of KLF4α block 
KLF4(FL)-mediated E-Cadherin RNA induction (left panel). As a control, different ratios KLF4(FL)/pCMV6 were used followed by qPCR 
for E-Cadherin levels. Note that even KLF4(FL)/pCMV6 ratio of 1:4 still robustly induced E-Cadherin (right panel). Data are expressed 
as the mean +/– SEM. n = 3. *p ≤ 0.05 (KLF4(FL) versus (FL)/α 3:2). **p ≤ 0.05 (KLF4(FL) versus pCMV6). (B) KLF4α/KLF4(FL) 
imbalance in MDA-MB-231 cells reduces KLF4(FL)-provoked p21Cip1 induction as evidenced by qPCR (left panel). Right panel shows 
the control using different KLF4(FL)/pCMV6 ratios. Data are expressed as the mean +/– SEM. n = 3. TBP: TATA-Box binding protein. 
*p ≤ 0.05 (KLF4(FL) versus (FL)/α 3:2). **p ≤ 0.05 (KLF4(FL) versus pCMV6). (c) MDA-MB-231 cells were transiently transfected with 
different ratios of KLF4α and KLF4(FL) followed by immunoblot analysis using specific antibodies for E-Cadherin and p21Cip1. Note that 
KLF4α/KLF4(FL) imbalances are reflected on protein levels as assessed by anti-KLF4 (KLF4(FL)) and anti-myc (KLF4α) and abrogate 
E-Cadherin and p21Cip1 inductions. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. *background band.
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KLF6-v1 in prostatic tumors [35]. To our knowledge, 
nothing is known yet about polymorphisms within crucial 
splice-site regions for the KLF4 gene in tumors. Further 
studies are needed to address the important questions of 
KLF4 splicing deregulation in tumors. 
KLF4α expression was initially identified in 
pancreatic cancer [26]. In pancreatic cancer patients, high 
KLF4α levels were associated with an aggressive tumor 
phenotype and poor survival. Pancreatic tumor models 
showed that KLF4α over-expression resulted in larger 
tumors, due to increased cancer cell proliferation [26]. 
Our data on KLF4α in breast cancer mostly confirms this 
study with some significant novel additions and relevant 
differences: (i) Compared to Wei et al. [26] our sequencing 
analysis showed that MDA-MB-231 cells contain a KLF4 
protein with nine additional N-terminal amino acids 
(MRQPPGESD) corresponding to the EMBL Nucleotide 
Sequence Database accession number HF546201. This 
N-terminal variance in KLF4 has recently been identified 
and characterized for the potential of reprogramming [39]. 
(ii) KLF4α expression has been described in pancreatic 
and prostatic cancer only [25, 26]. We extended this 
expression analysis by screening a total of 25 human 
cancer cells from 11 different tissues and identified KLF4α 
transcripts in 21 out of the 25 cell lines tested (84%). These 
results indicate that KLF4α is widely expressed in human 
tumors and that our findings in breast cancer may have 
relevance in other tumors as well. (iii) While KLF4α was 
Figure 6: KLF4α sequesters KLF4(FL) in the cytoplasm. (A) MDA-MB-231 cells co-transfected with a 1:1 mix of KLF4(FL)-
myc and pCMV6, and stained 24 h after transfection. Two sample images are shown. KLF4(FL)-myc is mostly located in the nucleus 
overlapping with the Hoechst stain. scale bar: 20 µm. (B) MDA-MB-231 cells transfected with a 1:1 mix of KLF4(FL) and KLF4α-myc, 
and stained 24 h after transfection. Two sample images are shown. In KLF4α-positive cells, KLF4(FL) is often localized in the cytoplasm. 
In the bottom row, the dotted line indicates a KLF4α-negative cell that displays an exclusive nuclear staining for KLF4(FL). Hoechst 
staining to indicate the nuclei is shown in blue. scale bar: 20 µm. (c) Linescan plots of the three cells in panel B, bottom are shown. 
Note, while in the absence of KLF4α the linescan plots for KLF4(FL) (green line) and Hoechst (blue line) are almost identical (indicating 
strict nuclear KLF4(FL) expression in cell 1), presence of KLF4α alters KLF4(FL) localization (cell 2 and 3). (d) Quantification of the 
co-transfection experiments. 100 KLF4α-positive cells were analyzed for the exclusive nuclear localization of KLF4(FL) (n = 3). Graph 
shows difference of percentage of cells having strict nuclear KLF4(FL) expression in the KLF4(FL)/pCMV6 versus the KLF4(FL)/KLF4α 
co-transfected cells. *p ≤ 0.05 (KLF4(FL)/pCMV6 versus KLF4(FL)/KLF4α). (e) Nuclear extracts of MDA-MB-231 cells co-transfected 
with different ratios of KLF4α/KLF4(FL) analyzed by immunoblots. Note that altering the KLF4α/KLF4(FL) ratio decreases nuclear 
KLF4(FL) levels compared to the respective ratios of KLF4(FL)/pCMV6. Nuclear extracts were defined by the presence of LaminA/C and 
the absence of GAPDH. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. *background band. (F) Co-immunoprecipation analysis 
of the association between KLF4α and KLF4(FL) using total cell extracts of MDA-MB-231 cells transiently transfected with a 1:1 ratio 
KLF4α-myc/KLF4(FL) 36 h after transfection. Total cell extract (input) was used as control in western blots. Immunoprecipitation with 
α-myc followed by western blot with α-KLF4 detects a specific band at 65kDa, which corresponds to KLF4(FL). Bottom panel shows that 
anti-myc (9E10) immunoprecipitated KLF4α-myc successfully. 
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not expressed in normal pancreatic tissue [26], we clearly 
established KLF4α expression in normal tissues. In our 
limited set of normal human tissues, KLF4α was readily 
detectable in all of them (breast, kidney, lung, and ovary). 
(iv) KLF4α expression was absent in normal pancreas, but 
correlated with tumor grade in pancreatic cancer patients 
[26]. We did not identify higher KLF4α levels in kidney, 
lung, and ovarian cancer patients compared to their 
respective controls. A tendency towards increased KLF4α 
levels compared to control was only observed in breast 
cancer patients. It is evident that larger sample numbers 
will be required to further clarify this point. However, 
we believe that not KLF4α levels per se are important 
for its actions, but rather that the KLF4α/KLF4(FL) ratio 
determines whether KLF4α can antagonize KLF4(FL) 
or whether KLF4(FL) can mediate its transcriptional 
gene regulation. Most of the tumor samples analyzed in 
this study displayed a significant increase of the KLF4α/
KLF4(FL) ratio compared to controls. Tumors can achieve 
this imbalance either by increased expression of KLF4α, 
or by reduced levels of KLF4(FL). Numerous studies 
report a loss of KLF4(FL) expression in tumors (e.g., 
[3]), suggesting that KLF4(FL) prevents tumor formation. 
However, it is reasonable to hypothesize that not the loss 
of KLF4(FL) per se is tumorigenic, but that a potential 
resulting increase of KLF4α/KLF4(FL) ratio might 
stimulate tumor growth. Therefore, future studies should 
analyze KLF4(FL) as well as KLF4α levels in cancer 
Figure 7: KLF4α stimulates proliferation in MDA-MB-231 cells. (A) Forced over-expression of KLF4α in MDA-MB-231 cells 
results in changes of the actin network as evidenced by phalloidin (red). Note the prominent cortical actin in KLF4α expressing cells as 
compared to control. (B) While forced expression in the normal breast cell line MCF10A does not alter cell growth, it does stimulate 
proliferation in the breast cancer cell lines T47D and MDA-MB-231. Two different assays were used: Top and bottom left panels show the 
result of counting the cells after the indicated times. The bottom right panel displays BrdU incorporation. *p ≤ 0.05 (KLF4α versus pCMV6).
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patients. (v) We used a cellular model which allowed us 
to specifically manipulate the KLF4α/KLF4(FL) ratio 
and to follow the effects of altered KLF4α/KLF4(FL) 
ratios on E-Cadherin and p21Cip1. In transfected MDA-
MB-231 cells, a KLF4α/KLF4(FL) mix of 1:1 was 
sufficient to inhibit KLF4(FL)-mediated regulation of the 
transcriptional targets E-Cadherin and p21Cip1. Importantly, 
these artificially generated KLF4α/KLF4(FL) ratios are in 
the range of the ratios observed in tumor patients. 
In summary, this is the first study on KLF4α 
expression in breast cancer. We show that KLF4α is 
expressed in various normal tissues, but that tumors 
display an increase of the KLF4α/KLF4(FL) ratio 
compared to control. We demonstrate that although 
KLF4(FL) acts as a tumor-inhibiting gene in MDA-
MB-231 cells, an increased KLF4α/KLF4(FL) ratio 
is able to oppose this effect. KLF4α interacts with 
KLF4(FL) in the cytoplasm, which prevents nuclear 
localization of KLF4(FL), thereby inhibiting KLF4(FL) 
tumor-suppressive functions in the nucleus, such as 
growth inhibition. These results warrant further studies 
on the role of KLF4α in tumorigenesis using larger sets 
of clinical samples. Future studies should be aimed 
at analyzing whether targeted inhibition of KLF4α 
suppresses breast cancer cell growth. Also, it will be 
interesting to see how KLF4α/KLF4(FL) imbalance 
affects the cancer stem cell-like population, which plays 
an important role in tumor development and emergence 
of therapy-resistant clones in breast cancer. Finally, it 
has to be analyzed whether presence of KLF4α, a KLF4 
antagonist, might be an important, so far neglected player 
in the generation of induced pluripotent stem cells. 
MAtEriALs AnD MEthoDs
cell culture, transfection, stable cells
MDA-MB-231 were purchased from the American 
Cell Type Culture collection, and cultured according to 
the manufacturer’s instructions under standard conditions. 
Supplementary Table S1 lists all cell lines used in this study. 
For transfections, cells were split the day before so 
that they reached 60-70% confluence. Transfections were 
performed using JetPei (Polyplus, Illkirch-Graffenstaden, 
France) following their protocol with 1 µg DNA and 2 µl 
JetPei reagent per 35 mm dish. 5 h after transfection, the 
transfection mix was removed and cells were replenished 
with fresh medium. Cells were analyzed 24 - 48 h post-
transfection.
For the generation of stable MDA-MB-231 cells, 
expression plasmids (backbone vector: pCMV6-A-Puro, 
Origene, Rockville, USA) containing a puromycin selection 
marker were used for transfection. 24 h after transfection, 
puromycin-selection was started (2 µg/ml; Sigma-Aldrich, 
St. Louis, USA). Every other day, fresh medium including 
puromycin was added and selective pressure maintained 
until the emergence of resistant cell clones. Stable cells 
were characterized by quantitative real-time PCR (qPCR), 
immunofluorescence, and immunoblotting.
For the over-expression experiments, pools of cells 
have been used and experiments have been repeated at 
least three times after independent transfections.
Cloning of the KLF4 constructs
cDNA was synthesized from total RNA extracted 
from MCF10A and MDA-MB-231 cells. PCR was 
performed on the cDNA’s using Taq Polymerase 
(Roche, Rotkreuz, Switzerland) and the following 
primers: 5′-ATGAGGCAGCCACCTGGCGAG-3′/5′- 
CATCGGAGCGGGCGAATTTCC-3′. Amplicons were 
separated on agarose gels, purified using the QIAquick 
Gel Extraction kit (QIAGEN, Hilden, Germany) and then 
used for sequencing.
To generate a myc-tagged KLF4(FL) expression 
plasmid, the following primers were used: 5′-TGCGATC 
GCCATGAGGCAGCCACCTGGCGAGTCTG-3′/5′- ATA 
CGCGTAAAATGCCTCTTCATGTGTAAGGC-3′. The 
primer set 5′-ATGCGATCGCCATGAGGCAGCCACCT 
GGCGAGTCTG-3′/ 5′-ATACGCGTGTTCATCTGAGC 
GGGCGAATTTC-3′ was used for cloning a myc-tagged 
KLF4α expression construct. Primers contained an AsiSI 
(forward primer) and a MluI restriction sites (reverse 
primer), respectively. This allowed the directional cloning 
into the mammalian expression plasmid pCMV6-A-Puro 
(Origene) containing a myc tag. All expression plasmids 
were sequence-verified. 
rnA extraction, cDnA synthesis, qPCr analysis
Total RNA was isolated from approximately 80% 
confluent cells using the RNeasy Mini Kit (QIAGEN). Total 
RNA was further purified by the Turbo DNAse Treatment 
and Removal kit (ThermoFisher Scientific, Lucerne, 
Switzerland). cDNA was synthesized from 1 µg total RNA 
using the High Capacity cDNA Reverse Transcription kit 
(ThermoFisher Scientific). mRNA levels were quantified 
by qPCR using Platinum SYBR Green qPCR SuperMix-
UDG with ROX (Invitrogen) on an ABI StepONE Plus 
Instrument (40 cycles of 95°C for 15 s and 58°C for 30 s). 
Relative expression was calculated using the ΔΔCT method, 
normalizing values to TATA-Box binding protein (TBP) 
within each sample; standard error of the mean (SEM) was 
calculated from the results of triplicates. All primers were 
tested for specificity and efficiency. Primers used are listed 
in Supplementary Table S2.
TissueScan Real-Time Arrays were obtained from 
Origene. qPCR analysis of the TissueScans was performed 
according to their manual.
Total RNA from human breast tissues (ductal 
carcinoma) and a matched pair RNA sample from breast 
tissue were purchased from Amsbio (Abingdon, UK). 
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Western blotting
Cell extracts were prepared in RIPA buffer as 
described [40]. Alternatively, cultures were rinsed with 
phosphate-buffered saline (PBS), drained, and lysed in 
reducing Laemmli sample buffer. After boiling the samples 
for 5 min at 95°C, proteins in Laemmli buffer were 
separated by SDS-PAGE under reducing conditions and 
blotted to polyvinyl-difluoride membranes (ThermoFisher 
Scientific). Then, membranes were stained with amido 
black to control for equal protein loading and blotting 
efficiency. After blocking for 1 h at room-temperature 
in Tris-buffered saline (TBS) containing 0.05% Tween 
and 5% skim milk powder (Sigma-Aldrich), membranes 
were incubated over-night with primary antibodies at 4°C. 
Membranes were washed three times in TBS-Tween and 
incubated for 1 h with peroxidase-conjugated anti-rabbit/
mouse IgG at room temperature. Blots were developed 
using SuperSignal West Dura (ThermoFisher Scientific) 
and exposed to Super RX Fuji Medical X-Ray films 
(Fujifilm, Diesldorf, Switzerland).
Primary antibodies used: anti-myc (clone 9E10), 
anti-KLF4 (ab151733) and anti-GAPDH (ab9485, all 
from Abcam, Cambridge, UK), anti-LaminA/C (#612162, 
BD Biosciences, East Rutherford, USA), anti-E-Cadherin 
(#3195), anti-p21Cip1 (#2947), and anti-p27Kip1 (#3686, all 
from Cell Signaling Technologies, Danvers, USA). The 
KLF4α-specific antibody GN330 [26] was a generous gift 
from Profs. Keping Xie and Daoyan Wei (MD Anderson 
Cancer Center, University of Texas, USA).
Some Western Blots were analyzed densitometrically 
using ImageJ software version 1.51a (NIH, Bethesda, MD; 
http://rsbweb.nih.gov/ij). Briefly, the total band intensity 
of the protein of interest was normalized to the GAPDH 
band intensity of the same extract in the same experiment.
Cytoplasmic and nuclear protein extraction
For preparation of cytoplasmic and nuclear cell 
extracts, cells grown in 10 cm dishes were washed in 
ice-cold PBS and lysed in lysis buffer (10 mM HEPES 
pH 7.9, 100 mM KCl, 1 mM EDTA, 1 mM DTT, 0.5% 
NP-40 and protease inhibitor cocktail (Roche)). After 
centrifugation, supernatants were collected as cytoplasmic 
fractions. Nuclear pellets were washed with lysis buffer 
lacking NP-40, and extracted with 250 mM Tris-HCl 
pH 7.8, 100 mM KCl, 1 mM EDTA, 1 M DTT, 0.5% 
NP-40, 20% glycerol shaking at 4°C for 1 h, followed 
by centrifugation to clarify the nuclear extracts. Proper 
fractionation was confirmed by GAPDH and LaminA/C 
presence as cytoplasmic and nuclear marker, respectively.
Co-immunoprecipitation
For co-immunoprecipitations (co-IP), cells grown in 
10 cm dishes were lysed in ice-cold co-IP buffer (50 mM 
Tris-HCl, pH 7.4, 1% Triton-X-100, 25 mM Hepes, 150 
mM NaCl, 0.2% Sodium deoxycholate, 5 mM MgCl2 
and protease inhibitor cocktail Roche). Cell lysates were 
incubated for 60 min on a rotary wheel at 4°C. After 
centrifugation for 15 min at 13200 rpm, the supernatant was 
transferred into a new 1.5 ml tube and protein concentration 
measured by a Bradford Assay (Expedeon, Swavesey, UK). 
Equal amounts of cell lysates (200 µg) were pre-cleared 
for 1 h at 4°C on a rotary wheel. Pre-cleared lysates were 
incubated with 3 µg of anti-myc (9E10) antibody or 3 µg of 
control mouse IgG (mAB002, R&D Systems, Minneapolis, 
USA) and incubated over-night at 4°C on a rotary wheel. 
Dynabeads Protein G (Life Technologies) were added to 
the immunocomplexes and incubated for 1 h at 4°C on a 
rotary wheel. After 3 washes with co-IP buffer, complexes 
were eluted in denaturing SDS sample buffer, resolved by 
SDS-PAGE and analyzed by immunoblotting
immunofluorescence and quantification
For stainings, cells were grown in 35 mm dishes 
containing four separate wells (Greiner Bio-One, 
Frickenhausen, Germany). Cells were washed twice with 
PBS before fixation in 4% paraformaldehyde at room-
temperature. Afterwards, cells were washed three times 
with PBS, permeabilized in 0.1% Triton-X-100 for 5 min 
and incubated with primary antibody for 2 h at room-
temperature. After three PBS rinses, cells were incubated 
with fluorescent-labeled secondary antibodies (Molecular 
Probes) for 1 h in the dark, rinsed with PBS and coverslip-
mounted with ProLong Gold antifade reagent (Molecular 
Probes). Hoechst was added to the last washing step. Cells 
were examined and photographed using an Axioskop 
microscope (Carl Zeiss MicroImaging, Oberkochen, 
Germany) connected to an ORCA-ER digital camera 
(Hamamatsu, Solothurn, Switzerland).
Linescan plots were performed using ImageJ 
software version 1.51a. Briefly, a line, spanning an entire 
cell, was drawn and the gray intensities along the line 
(through the cell) were plotted. 
 For quantification, 100 cells per experimental 
group were analyzed in triplicates. KLF4(FL) in KLF4α-
positive cells was categorized as “strictly nuclear” or 
“nuclear+cytoplasmic”. Quantification was blinded and 
performed by two lab members. 
Cell growth
Cell growth was analyzed by two different methods. 
First, 9 × 104 cells were plated into 35 mm dishes in 1% 
FCS-containing medium. At the indicated time points, 
cells were trypsinized and counted. The increase in cell 
population was calculated as fold induction compared to the 
time-point 0. Second, the fraction of cells within S phase 
was determined using a 5-bromo-2′-deoxyuridine (BrdU) 
incorporation assay (Roche) as described in their manual. 
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Briefly, 5 × 103 cells were plated into black 96-well plates 
with clear, flat bottom (PerkinElmer, Waltham, USA) in 1% 
FCS-containing medium. Cells were allowed to proliferate 
for the indicated times before labeling with BrdU for 2 h at 
37°C. Afterwards, cells were fixed for 30 min, and incubated 
with the anti-BrdU antibody conjugated with peroxidase for 
90 min, followed by extensive washing. BrdU substrate 
was added and incubated for 3 min before measuring 
chemiluminescence signals using a Mithras LB940 
luminometer (Berthold Technologies, Zug, Switzerland).
Statistical analysis
Data are represented as means and standard 
deviation/standard error of the mean (SD/SEM) as stated 
in the figure legends. Statistical analysis using a two-
tailed t-test was carried out either at www.physics.csbsju.
edu/stats/t-test.html or with the program GraphPadPrism 
Version 5. All experiments have been performed at least 3 
times in triplicates. The difference between two data sets 
was statistically significant when p ≤ 0.05.
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